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Virus-specific cytotoxic T lymphocytes (CTL) with high levels of functional avidity have been associated with
viral clearance in hepatitis C virus infection and with enhanced antiviral protective immunity in animal
models. However, the role of functional avidity as a determinant of HIV-specific CTL efficacy remains to be
assessed. Here we measured the functional avidities of HIV-specific CTL responses targeting 20 different,
optimally defined CTL epitopes restricted by 13 different HLA class I alleles in a cohort comprising 44 HIV
controllers and 68 HIV noncontrollers. Responses restricted by HLA-B alleles and responses targeting epitopes
located in HIV Gag exhibited significantly higher functional avidities than responses restricted by HLA-A or
HLA-C molecules (P  0.0003) or responses targeting epitopes outside Gag (P < 0.0001). The functional
avidities of Gag-specific and HLA-B-restricted responses were higher in HIV controllers than in noncontrollers
(P 0.014 and P 0.018) and were not restored in HIV noncontrollers initiating antiretroviral therapy. T-cell
receptor (TCR) analyses revealed narrower TCR repertoires in higher-avidity CTL populations, which were
dominated by public TCR sequences in HIV controllers. Together, these data link the presence of high-avidity
Gag-specific and HLA-B-restricted CTL responses with viral suppression in vivo and provide new insights into
the immune parameters that mediate spontaneous control of HIV infection.
A small number of human immunodeficiency virus (HIV)-
infected individuals, comprising approximately 0.5% of all
cases, are able to control the infection in the absence of anti-
retroviral treatment. Such individuals exhibit low to undetect-
able virus loads in the peripheral blood and show either no or
minimal signs of HIV disease progression; they are therefore
referred to as “controllers” or “long-term nonprogressors”
(LTNP) (26). Elucidating the mechanisms that are involved in
the relative control of viral replication in these individuals is
essential for our understanding of HIV pathogenesis and could
crucially inform vaccine development (18).
CD8 cytotoxic T lymphocytes (CTL) are considered an
important component of immune defense against HIV and
viral pathogens in general. The most compelling evidence for
their protective role in HIV infection comes from the follow-
ing: (i) studies that show a temporal association between the
appearance of CTL responses and the initial early decline of
plasma viremia (45), (ii) CD8 T-cell depletion experiments in
the nonhuman primate simian immunodeficiency virus (SIV)
model (70), and (iii) the finding that certain HLA class I alleles
are enriched in subjects with delayed disease progression (re-
viewed in reference 59). Interestingly, a recent genome-wide
association analysis comparing HIV controllers and noncon-
trollers identified specific amino acids in the peptide binding
grooves of HLA-B molecules that could enable these alleles to
restrict particularly potent CTL responses (64). However, de-
spite the large number of studies characterizing HIV-specific
T-cell responses, the hallmarks of a truly protective immune
response remain unclear.
Neither the total breadth nor the magnitude of the overall
virus-specific CTL response associates with the outcome of
HIV disease (1, 32). However, CTL responses restricted by
specific HLA-B alleles and responses that target the Gag pro-
tein appear to be particularly effective in vivo (43, 87). None-
theless, some individuals with progressive disease also carry
protective HLA alleles and mount broad Gag-specific CTL
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responses, indicating the presence of other factors that deter-
mine in vivo immune efficacy. One parameter that has repeat-
edly been associated with the control of viral replication in
animal models is the functional avidity of virus-specific CTL (2,
9, 27). High-functional-avidity T cells feature a superior ability
to recognize virally infected cells even at low surface antigen
densities and deploy effector functions at lower cognate anti-
gen concentration thresholds than do low-avidity T-cell popu-
lations (10, 14). In humans, such high-avidity CTL have been
associated with clearance of hepatitis C virus (HCV) infection
and broad recognition of HCV epitope variants (86). Although
not necessarily directly linked, these data suggest that high-
avidity CTL responses may be especially effective at controlling
infections with highly variable pathogens, since variant recog-
nition may be crucial for the limitation of immune escape (25).
Furthermore, in HIV infection, the Nef protein downregulates
HLA class I molecules on the surfaces of infected cells; in this
setting, high-avidity CTL responses could provide a crucial
advantage by recognizing HIV-infected cells despite the reduc-
tion in surface antigen density (8, 9, 24). The presence of
high-avidity CD4 T cells in HIV controllers and the emer-
gence of escape mutants as a direct consequence of immune
selection pressure mediated by high-avidity CTL provide sup-
port for the important role of functionally avid responses in the
control of HIV/SIV replication (49, 61, 82).
In the current study, we directly tested the role of functional
avidity as a determinant of CTL efficacy in the control of HIV
replication. Furthermore, we examined the relationship be-
tween this parameter and antigen specificity, in terms of both
the targeted HIV-derived epitopes and their associated HLA
class I restriction elements.
MATERIALS AND METHODS
Study subjects. All study participants were recruited from previously described
cohorts in the Boston, MA, area (33, 64). HIV loads were determined using
Roche Amplicor tests with a lower detection limit of 50 copies/ml. HLA typing
was performed as described previously using sequence-specific primer PCR
(SSP-PCR) (30). The Partners Human Research Committee at Massachusetts
General Hospital approved all human subject research protocols, and all subjects
provided written informed consent prior to enrollment. Responses were com-
pared between 44 subjects with spontaneous control of HIV replication to less
than 2,000 RNA copies/ml (“controllers”; median viral load  50 copies/ml;
range, 50 to 2,000 copies/ml) and 68 untreated subjects with viral loads greater
than 3,000 RNA copies/ml (“noncontrollers”; median viral load, 38,450 copies/
ml, range, 3,900 to 604,000 copies/ml). For experiments investigating the effects
of highly active antiretroviral therapy (HAART)-induced viral suppression on
CTL function, the functional avidities and magnitudes of CTL responses were
determined for 14 treated individuals before and after the initiation of HAART;
the median time on treatment at the second time point was 56.4 weeks (range, 1
to 150 weeks).
Peptide epitopes. A total of 20 well-defined and commonly recognized HIV
CTL epitopes listed at the Los Alamos HIV Immunology Database were in-
cluded in the present study (15, 33). These epitopes are restricted by 13 different
HLA-A (n  4), HLA-B (n  7) and HLA-C (n  2) molecules and are
summarized in Table 1. The antigenic peptides were selected to allow testing of
epitopes with the following characteristics: (i) they are restricted by alleles
commonly found in both HIV-controllers and noncontrollers, (ii) they are tar-
geted by a substantial proportion of individuals expressing the restricting al-
lele(s), and (iii) they can be presented in the context of different alleles (15, 33).
For additional experiments on the role of HLA alleles as determinants of func-
tional avidity, epitopes for which promiscuous presentation on multiple class I
alleles has been demonstrated (33) and which are also presented by HLA alleles
associated with controlled and noncontrolled HIV infection (60) were used as
indicated in the respective section.
IFN- ELISpot and functional avidity assays. Peripheral blood mononuclear
cells (PBMC) were isolated from whole blood using density gradient centrifu-
gation and tested ex vivo in gamma interferon (IFN-) enzyme-linked immu-
nosorbent spot (ELISpot) assays using single epitopes at a concentration of 14
g/ml (11). Functional avidity was determined as described previously (86). In
brief, unexpanded PBMC were thawed and rested for 4 h at 37°C and then
stimulated in IFN- ELISpot assays with peptides added in serial 10-fold dilu-
tions ranging from 100 g/ml to 10 pg/ml (33). A positive (phytohemagglutinin)
control well and at least four negative (no peptide) control wells were included
on each plate. Stimulations were set up in duplicates or triplicates if cell avail-
ability allowed. Results are expressed as spot-forming cells (SFC) per million
input cells. The threshold for a positive response was defined as at least five spots
per well at a peptide concentration of 10 g/ml and 3 mean background.
Functional avidity was calculated by sigmoidal dose (SD)-response curves fitted
to the ELISpot data using the GraphPad Prism software program (version 4.0).
T-cell receptor (TCR) repertoire analysis. Antigenic stimulation was per-
formed on thawed PBMC. Individual HIV peptides were used at 10 g/ml to
stimulate HIV-specific CD8 T cells for 14 h at 37°C in the presence of costimu-
lation with anti-CD28 and anti-CD49d monoclonal antibodies (1-g/ml [each]
final concentration; BD Biosciences). In every experiment, a negative control
(costimulation alone with anti-CD28/anti-CD49d) was included to account for
spontaneous stimulation, and a positive control (Staphylococcus enterotoxin B
[SEB], 1 g/ml, final; Sigma-Aldrich) was included to ensure that the cells were
responsive. After stimulation, the cells were surface stained with the following
monoclonal antibodies: anti-CD3-fluorescein isothiocyanate (FITC), anti-CD8-
Pacific Blue, anti-CD14-Cy5PE, anti-CD19-Cy5PE, anti-CD25-phycoerythrin
(PE), and anti-CD69-allophycocyanin (APC) (all from BD Biosciences). Viable
antigen-specific CD8 T cells were identified on the basis of CD3, CD8, CD25,
and CD69 coexpression as described previously for reactive T-cell populations
(66). Staining for CD14 and CD19 was used to exclude macrophages and B cells
from the analysis. Responding cell populations were sorted at 70 lb/in2 directly
into 1.5-ml microtubes (Sarstedt) containing 100 l RNAlater (Applied Biosys-
tems) using a modified FACSAria flow cytometer (BD Biosciences); sort purity
was 98% in all cases, and at least 1,000 cells were collected for each experi-
mental condition. Unbiased clonotypic analysis of all expressed TRB gene prod-
ucts was then conducted using a nonnested template-switch-anchored reverse
transcriptase PCR (RT-PCR) as described previously (28, 67). The entire pro-
cedure was performed blinded to the clinical status of the subjects in all cases.
Statistical analysis. The GraphPad Prism (version 4.0) software for Macintosh
was used for the 50% SD (SD50) determinations. The Mann-Whitney test was
used to compare the functional avidities of CTL responses between the two study
groups; the Kruskal-Wallis test and Dunn’s posttest were used to compare the
functional avidities of CTL responses across different restricting HLA alleles and
different viral proteins. A Spearman rank test was used to assess the relationship
between the functional avidities or magnitude of the CTL responses and the time
after initiation of HAART.
TABLE 1. Epitopes tested for functional avidity
Sequence HLA Protein
YFPDWQNYT A01 Nef
FLGKIWPSYK A02 Pol (p15)
ILKEPVHGV A02 Pol (RT)
SLYNTVATL A02 Gag (p17)
AIFQSSMTK A03 Pol (RT)
QVPLRPMTYK A03 Nef
AIFQSSMTK A11 Pol (RT)
QVPLRPMTYK A11 Nef
TPGPGVRYPL B07 Nef
TPQDLNTML B07 Gag (p24)
TPQVPLRPM B07 Nef
EIYKRWII B08 Gag (p24)
ELRSLYNTV B08 Gag (p17)
FLKEKGGL B08 Nef
TPQDLNTML B42 Gag (p24)
AEQASQDVKNW B44 Gag (p24)
QASQEVKNW B53 Gag (p24)
KAFSPEVIPMF B57 Gag (p24)
SFNCGGEFF Cw04 Env (gp120)
KRQEILDLWVY Cw07 Nef
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RESULTS
HLA-B-restricted and Gag-derived epitopes are targeted by
CTL responses with high levels of functional avidity. A num-
ber of studies in humans and animal models have aimed to
understand the impact that different major histocompatibility
complex (MHC) class I molecules exert on the quality and
quantity of the evolving CTL response (15, 42, 54, 64). This
issue is of particular importance in HIV infection, for which
specific HLA class I alleles have been associated with im-
proved in vivo control of viral replication (reviewed in refer-
ences 59 and 60). However, direct links between the attributes
of CTL-mediated immunity and the clinical control of HIV
infection have been addressed only in the context of a few
selected HLA alleles and individual epitopes or on the basis of
responses elicited by peptide pools spanning whole viral pro-
teins (4, 5, 13, 14, 40, 44, 49, 51, 55). To overcome these
limitations, we assessed the functional avidities of CTL re-
sponses to 20 optimally defined HIV-derived epitopes in a
cohort of 112 HIV-infected individuals with variable disease
progression rates and heterogeneous HLA backgrounds. The
epitopes included in this study spanned CTL targets in the
HIV Gag, Pol, Nef, and Env proteins, thereby also enabling
comparison of functional avidities across specificities from dis-
tinct viral gene products (Table 1). Of the 112 HIV-infected
individuals tested, functional avidities were defined for a total
of 199 distinct CTL responses, including 121 responses de-
tected in 68 noncontrollers and 78 responses detected in 44
controllers.
To test whether functional avidity was affected by the re-
stricting HLA molecule or the viral protein from which it was
derived, SD50 values were compared between responses re-
stricted by HLA-A, -B, or -C alleles and between epitopes
located in different viral proteins. CTL responses restricted by
HLA-B exhibited significantly higher functional avidities (me-
dian, 93.9 ng/ml; range, 8.37  108 to 16,312 ng/ml) than
those restricted by HLA-A (median, 761.6 ng/ml; range, 1.45 to
625,806 ng/ml; P 0.001). Although the median SD50 was also
higher than HLA-C allele-restricted responses, this compari-
son did not reach statistical significance (median, 651.5 ng/ml;
range, 0.01 to 17,255 ng/ml) (Fig. 1A). When responses to
different HIV proteins were compared, Gag-specific responses
displayed higher functional avidities than responses directed
against other individual proteins or all non-Gag-derived
epitopes combined (P  0.0001) (Fig. 1B and C). Together,
these data support an important role for HLA-B-restricted
responses in HIV control (42) and suggest that the significantly
higher functional avidities of Gag-specific responses might
contribute to their previously described efficacy (43, 87).
HIV controllers mount CTL responses with higher func-
tional avidities than noncontrollers. To further assess the rel-
evance of functional avidity in HIV control, we determined
whether epitope-specific CTL responses in controllers exhib-
FIG. 1. CTL responses targeting HLA-B-restricted and Gag-derived epitopes exhibit high levels of functional avidity. Epitope-specific re-
sponses were analyzed for 112 HIV-infected individuals (68 noncontrollers and 44 controllers). (A) The median functional avidity of 99
HLA-B-restricted responses was compared with the median functional avidities of 76 HLA-A-restricted and 24 HLA-C-restricted responses. (B
and C) Stratification for epitope localization by HIV protein. The median functional avidity of responses targeting Gag-derived epitopes was
compared with the median functional avidities of responses directed against epitopes derived from Pol, Nef, and Env. The box plots represent the
functional avidities of all epitopes tested in each group; median values, 25th and 75th percentiles, and ranges are displayed. The Kruskal-Wallis
test followed by Dunn’s posttest for multiple comparisons was used to assess significance. ns, not significant; *, P  0.01 to 0.05; **, P  0.001
to 0.01; ***, P  0.001.
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ited intrinsically higher avidities than those in noncontrollers.
Where possible, comparable numbers of CTL responses were
tested for each epitope in either group (Fig. 2A). When the
SD50 values of all responses for HIV controllers (n  78
responses) and noncontrollers (n  121 responses) were com-
pared, significantly higher levels of functional avidity were de-
tected for controllers (median, 140.3 ng/ml; range, 8.37 108
to 625,806 ng/ml) than for noncontrollers (median, 327.5 ng/
ml; range, 0.066 to 23,168 ng/ml; P  0.047) (Fig. 2B). Strat-
ification by HLA allele demonstrated that the functional avid-
ities of responses restricted by HLA-B (P  0.0175) but not
HLA-A (P  0.38) or HLA-C (P  0.43) were significantly
higher for HIV controllers than for noncontrollers (Fig. 2C).
In both groups, we found no significant correlation between
the time since initial HIV infection and functional avidity (data
not shown). Furthermore, when responses were grouped ac-
cording to epitope source, only Gag-specific responses exhib-
ited significantly different functional avidities between HIV
controllers and noncontrollers (P  0.0143) (Fig. 2D).
Functional avidities and CTL response magnitudes decline
with suppression of viral replication by antiretroviral treat-
ment. Previous studies have suggested that viral load may drive
some of the observed differences in HIV-specific T-cell reac-
tivities (32, 73). To test whether low functional avidities could
be driven by high viral loads and consequently would be re-
stored to higher levels of functional avidity by antigen removal,
the functional avidities of CTL responses to 8 different
epitopes were assessed for 12 untreated individuals with
chronic HIV infection over a period of up to 3 years (median,
56.4 weeks; range, 1 to 151 weeks; total number of epitope-
specific responses tested, 14) both before and after the initia-
tion of highly active antiretroviral treatment (HAART). As
expected from previous reports (23, 62, 63), the magnitude of
13/14 responses declined over time during the treatment pe-
FIG. 2. HIV controllers mount CTL responses with higher functional avidities than noncontrollers. (A) Stacked bars indicate the numbers of
individuals (controllers or noncontrollers) tested for each epitope. (B) Comparing all responses, controllers exhibited significantly higher functional
avidities than noncontrollers. (C) Functional avidities are shown for controllers and noncontrollers after stratification of responses according to
the restricting HLA molecule. Epitope-specific responses restricted by HLA-B but not HLA-A or HLA-C showed higher functional avidities with
controllers (gray-shaded boxes) than with noncontrollers (white boxes). (D) Gag-derived epitopes but not non-Gag-derived epitopes elicited
responses with higher functional avidities with controllers (gray-shaded boxes) than with noncontrollers (white boxes). ns, not significant.
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riod (P  0.003) (Fig. 3A). Indeed, the duration of HAART
was inversely associated with the reduction in CTL response
magnitudes, supporting previously described gradual decreases
over the period of suppressed antigenemia (P  0.012) (Fig.
3B). Rather unexpectedly, however, the functional avidities of
these responses were higher at the pretreatment time points
(median SD50, 146.3 ng/ml) than for samples obtained during
HAART (median SD50, 324.9 ng/ml; P  0.051) (Fig. 3C).
Functional avidity seemed to decline in relation to the duration
of HAART treatment; this correlation, however, was not sig-
nificant (Fig. 3D) (P  0.16). Although treatment-induced
viral suppression may not have the same effects on viral avidity
as viral suppression by the immune system, these data suggest
that antigen suppression during the chronic stages of uncon-
trolled HIV infection does not restore higher levels of func-
tional avidity and that CTL response magnitude and functional
avidity could be differentially regulated.
CTL responses to protective epitopes restricted by HLA-B27
and HLA-B57 exhibit the highest functional avidities. Among
the many peptides presented by HLA class I alleles associated
with superior HIV control, only a few optimally defined
epitopes have been specifically implicated in the suppression of
viral replication in vivo (21, 31, 35, 36). The most consistent of
these are the HLA-B27-restricted KRWIILGLNK epitope
(B27-KK10) and the HLA-B57-restricted KAFSPEVIPMF
epitope (B57-KF11), both of which are located in HIV Gag
p24. Since responses to these epitopes may contribute dispro-
portionately to the observed association between Gag-specific
responses and relative HIV control, we assessed the functional
avidities of these responses in detail. Consistent with their
apparent in vivo efficacy, both the B27-KK10 and B57-KF11
epitopes elicited in vitro responses with significantly higher
functional avidities than those for the other epitopes, indepen-
dent of clinical status (P  0.0003 and P  0.0006 for B27-
KK10 and B57-KF11, respectively) (Fig. 4A and B). Of note,
the median functional avidities of responses to these two spe-
cific epitopes were not significantly different for controllers
from those for noncontrollers (13.46 ng/ml versus 201.4 ng/ml
for B27-KK10 [P  0.268]; 152.0 ng/ml versus 443.9 ng/ml for
B57-KF11 [P  0.200]; data not shown). This could be attrib-
uted partly to smaller samples sizes for this subanalysis but may
also indicate that other mechanisms contribute to the lack of
FIG. 3. HAART-mediated suppression of viral replication does not select for high-avidity CTL responses. Functional avidities and magnitudes for
a total of 14 different epitope-specific CTL responses were quantified for 12 individuals with chronic HIV infection before and after the initiation of
HAART. For epitopes tested for more than one individual, mean values and standard deviations are indicated. (A) CTL response magnitudes were
measured in IFN- ELISpot assays before and after the initiation of HAART; fold change between the untreated and treated time points is displayed
in each case. (B) Changes in CTL response magnitudes versus time after the initiation of HAART (Spearman rank test). (C) Functional avidities of CTL
responses were measured before and after the initiation of HAART; log change between the untreated and treated time points is displayed in each case.
(D) Changes in the functional avidities of CTL responses versus time after the initiation of HAART (Spearman rank test).
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viral control in the rare individuals who express protective
HLA alleles but fail to control the infection (20, 57).
To assess whether CTL responses to these two epitopes were
also driving the overall associations between high levels of
functional avidity, HLA-B restriction, and the targeting of
epitopes in Gag, we repeated the analyses after excluding B27-
KK10 and B57-KF11 from the data set. Despite the reduced
number of CTL responses analyzed, HLA-B-restricted re-
sponses still exhibited higher functional avidities than re-
sponses restricted by HLA-A alleles (P  0.02). Similarly, the
statistically significant difference in the functional avidities of
responses to Gag-derived versus non-Gag-derived epitopes
persisted (P  0.0069). Thus, while the B27-KK10 and B57-
KF11 responses showed the most pronounced effects, in line
with their particular protective efficacy in vivo, the remaining
HLA-B-restricted and Gag-derived epitope-specific responses
still showed significantly higher functional avidities than re-
sponses to epitopes restricted by HLA-A alleles and responses
to non-Gag-derived epitopes, respectively.
High functional avidities to specific epitopes relate to the
presenting HLA allele. Several previous studies have demon-
strated that promiscuous presentation of specific CTL epitopes
by different HLA class I alleles is not uncommon (22, 30, 33,
51, 53, 77). Indeed, the vast majority of known optimal CTL
epitopes derived from HIV and Epstein-Barr virus (EBV) are
effectively presented by several different and unrelated HLA
class I alleles (33). Employing such promiscuous epitopes al-
lows the impact of the presenting HLA class I molecule on the
quality of the epitope-specific CTL response to be studied
more directly, avoiding potential biases related to protein
abundance and epitope processing. Based on an earlier report
(33), epitopes presented by HLA alleles that are differentially
associated with HIV disease control were selected for this
purpose (52, 60). The functional avidities of responses to five
such epitopes were compared in the context of their originally
described and alternative restricting alleles (Fig. 5A to H). As
controls, an additional three epitopes were included that are
promiscuously presented by HLA class I alleles for which no
strong association with HIV control, either good or bad, has
been reported. In all cases tested, the alleles associated with
better control of HIV replication restricted responses with
higher functional avidities than the alleles associated with a
less beneficial HIV disease outcome, showing a strong trend
toward statistical significance (P  0.08) (Fig. 5I). The func-
tional avidities of CTL responses restricted by the original or
alternative alleles were not significantly different (P 0.2) (not
shown), demonstrating that responses restricted by “alterna-
tive” HLA class I alleles can represent functionally relevant
responses. Collectively, these data indicate that the nature of
the presenting HLA allele can profoundly influence the func-
tional avidities of the CTL responses that it restricts. This
observation is in line with recent data describing an important
role for the presenting HLA molecule in HIV control (64) and
a previous analysis of HIV clade C-derived epitopes presented
in the context of different alleles in the HLA-B7 supertype, in
which the more beneficial allele restricted responses with
higher functional avidities (49).
High-avidity responses in controllers exhibit narrow and
highly skewed TCR repertoires. Next, we examined the func-
tional avidities of CTL responses in relation to their composite
T-cell receptor (TCR) repertoires, which act as counterparts to
the targeted peptide/MHC complex and determine the conse-
quences of antigen engagement. The definition of functional
avidity directly ex vivo is based on the antigen concentration-
dependent reactivity of the entire epitope-specific CTL popu-
lation, which potentially comprises multiple cognate TCR
clonotypes. Some of these clonotypes may be shared between
individuals, even in CTL populations that target the same
epitope presented by different HLA molecules (51, 77, 79).
Such “public” clonotypes display variable degrees of interindi-
FIG. 4. Responses restricted by HLA alleles associated with superior control of HIV infection exhibit high levels of functional avidity. The
functional avidities of CTL responses specific for two Gag-derived epitopes restricted by the protective alleles HLA-B27 and HLA-B57 were
compared either with those measured for all other tested epitope-specific responses, regardless of allelic restriction, or with those for all other
HLA-B-restricted responses. CTL responses to B27-KK10 (A) or B57-KF11 (B) showed higher median functional avidities than either other
HLA-B-restricted responses or all other responses studied. The box plots represent the functional avidities of all epitopes tested in each group;
median values, 25th and 75th percentiles, and ranges are displayed.
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vidual sharing and have been associated with protective effects
in response to a conserved immunodominant Gag-derived
epitope during acute SIV infection (65, 78, 81). To determine
whether the high-avidity responses in controllers were linked
to particular features of the corresponding antigen-specific
TCR repertoires, quantitative molecular analyses of clonotype
composition were conducted for three paired epitope-specific
responses that were each detectable in one HIV controller and
an HIV noncontroller: (i) the HLA-B53/B58-restricted QW9
epitope (Fig. 6, top panels), (ii) the HLA-B42-restricted TL9
epitope (Fig. 6, middle panels), and (iii) the HLA-B27-re-
stricted KK10 epitope (Fig. 6, bottom panels). For all three
epitope-specific responses, the HIV controllers exhibited nar-
rower TCR repertoires than the noncontrollers. Furthermore,
these narrower repertoires were markedly skewed in two of the
controllers (Fig. 6, F7174 and L8190). The public TCR se-
quences that were shared between the three pairs of individ-
uals in all cases dominated the TCR in the HIV controllers.
The functional avidities of the KK10-specific responses re-
stricted by HLA-B27 and the QW9-specific responses re-
stricted by HLA-B53/58 were higher in the controllers than in
the noncontrollers (data not shown), despite similar peptide
affinities for the different restriction elements in the latter case
(46 nM versus 9.7 nM) (15). In contrast, the functional avidity
of the TL9-specific response restricted by HLA-B42 for the
noncontroller was slightly higher than that of the correspond-
FIG. 5. Responses to promiscuously presented epitopes exhibit higher functional avidities in the context of HLA class I alleles associated with
better disease outcome. The functional avidities of CTL responses to epitopes presented in the context of different HLA class I alleles were
determined for untreated individuals with chronic HIV infection. (A to E) CTL responses in individuals expressing HLA class I alleles associated
with better control (“good alleles,” red lines) or accelerated disease progression (“bad alleles,” blue lines) were compared with responses to the
corresponding epitopes presented in the context of alleles with neutral disease outcome (black lines). (F to H) Epitopes promiscuously presented
on alleles associated with average rate of HIV disease progression were included as controls. (I) To allow exploratory statistical comparisons,
avidities of the response restricted by the “more beneficial” allele were compared to the avidities of those for the “less beneficial” allele for each
epitope tested in different HLA contexts. Responses to epitopes restricted by HLA class I alleles associated with a more beneficial disease outcome
showed a strong trend toward higher functional avidities than those of the corresponding responses restricted by less beneficial alleles. Horizontal
red bars in panel I represent median values.
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ing response for the controller (27.7 ng/ml versus 79.5 ng/ml;
data not shown). However, in this case, the noncontroller dis-
played a narrow and highly skewed TCR repertoire (Fig. 6,
F723). Thus, although limited to three pairs of epitope-specific
responses, these data indicate that high-avidity CTL responses
tend to be mediated by narrower TCR repertoires, which are
not invariably associated with, but may contribute to, superior
in vivo HIV control.
DISCUSSION
A number of recent studies have suggested an important
role for the functional avidity of CTL responses in the control
of viral infections (7, 86). However, many reports have been
based on responses to single epitope/HLA allele combinations
or have used T-cell cultures after in vitro expansion, which
could bias the resulting avidity measurements (4, 38, 86). Fur-
thermore, a comprehensive assessment of HIV-specific CTL
responses with respect to the role of functional avidity in the
control of viral replication is lacking. To address these issues,
we studied unexpanded CTL directly ex vivo in a cohort of
more than 100 HIV-infected individuals with varying disease
status and broad HLA class I allele distribution. Our data
confirm previous reports based on selected epitopes that link
the presence of high-avidity CTL populations to viral control
and further support the important role of HLA-B-restricted
responses targeting Gag-derived epitopes in antiviral immunity
(4, 6, 16, 38, 42, 44, 46).
Although directly supporting human experimental data are
scarce, it is likely that several different mechanisms are respon-
sible for such a superior immune function of HLA-B-restricted
CTL responses and the induction and maintenance of re-
sponses of elevated functional avidity. These possibly include
efficient epitope processing, the characteristics of the pre-
sented peptide on B alleles, and a particularly effective TCR
recognition of presented epitopes in the context of HLA-B
alleles. The HLA-B-restricted HIV epitope repertoire is
thought to be enriched for epitopes with increased sequence
conservation, which might limit viral escape from CTL-medi-
ated immune pressure and select for a narrower TCR reper-
toire of high avidity (29). Such selective presentation of more
conserved epitopes on HLA-B alleles could result from the
need for specific anchor residues for B alleles that require
amino acids that pose stringent functional and structural con-
straints on the viral protein and thus complicate viral escape.
Whether this would be specifically true for the protective
HLA-B alleles remains to be tested. Other than the need for
specific anchor residues, it is also plausible that structural dif-
ferences of the MHC molecules may influence the interaction
between the TCR and the peptide-MHC complex (pMHC)
(76), which could explain CTL responses of higher avidity to
epitopes presented by HLA B alleles (78, 83).
FIG. 6. High-avidity CTL responses in controllers are associated with narrow TCR repertoires. CDR3	 amino acid sequence, TRBV and TRBJ
usage, and relative frequency are shown for all clonotypes within each epitope-specific response. For each epitope, one controller and one
noncontroller pair was studied. Public clonotypes are color coded in the CDR3 sequence column and were identified as TCR	 amino acid
sequences observed for more than one individual with reference to an extensive database including unpublished data and data from previous
studies (4, 12, 34, 49, 50, 58, 80, 85). The IMGT nomenclature is used (48).
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Aside from HLA restriction, the fine specificity of HIV-
specific CTL has also been associated with relative control of
viral replication. In accordance with several previous studies
(43, 53, 87), the data presented here also link Gag-specific
responses with relative viral control and, likely of relevance in
mechanistic terms, with high levels of functional avidity. Since
Gag degradation products from the infecting viral particle are
presented very early after infection, high-avidity responses to
such cross-presented antigens could mediate the effective elim-
ination of infected cells at a relatively low surface density of the
represented epitopes and before the production of progenitor
virus (69). Furthermore, Gag is one of the most conserved
proteins in HIV and may contain a disproportionally high
number of epitopes that bind to alleles associated with supe-
rior HIV control, particularly HLA-B27 and HLA-B57. Since
these epitopes are among the most immunodominant ones in
individuals expressing these alleles (15, 33), they may be fo-
cusing the most beneficial response onto this protein (17).
Taken together, our data thus might suggest that high-avidity
CTL to Gag-derived, HLA-B-restricted epitopes contribute to
relative HIV control by targeting epitopes that (i) are ex-
pressed early in infection, (ii) could elicit cytolytic effector
functions at low epitope abundance on the surface (74), (iii)
are located in conserved regions with restricted viral escape
pathways, and (iv) might result in a more efficacious TCR
activation in the context of HLA-B alleles.
The differences in the median functional avidities between
controllers and noncontrollers, although statistically signifi-
cant, were surprisingly modest. This may be due in part to the
evident variability in SD50 values between different epitope-
specific responses. In addition, IFN- production is relatively
preserved in exhausted T cells and may be subject to compar-
atively low activation thresholds (13, 73). Thus, determining
SD50 values for additional effector functions may reveal more
marked differences between study groups, epitopes, and re-
stricting HLA alleles. Furthermore, functional avidity as tested
in our present study reflects the summation of CTL response
and epitope presentation, without taking into consideration
several additional factors that are likely important in deter-
mining the in vivo efficiency of these responses. For example,
epitope abundance on the surface of an infected cell will also
contribute to the in vivo effectiveness of the CTL response
independently of the experimentally measured functional avid-
ity using synthetic peptides. This amount of presented epitopes
on the cell surface is in turn impacted by several factors, such
as antigenic protein expression levels, epitope processing pref-
erences, intracellular epitope stability, HLA binding, HLA ex-
pression kinetics, and likely others (75). Data on these factors
are incomplete to date and are difficult to take into account
experimentally all at the same time, thus limiting the conclu-
sions that can be drawn from analyzing individual factors in
isolation. In vitro testing of functional avidity in the context of
HIV-infected cells might be one approach to bypass some of
the limitations of synthetic peptide-based assays and to reflect
the in vivo situation more directly. Practical limitations, how-
ever, would limit the feasibility of such studies for larger, ge-
netically heterogeneous host populations. Furthermore,
epitopes with the highest functional avidity in the present study
are not necessarily the epitopes with the highest intracellular
stability (47), which suggests that epitope stability is a possibly
independent factor, aside from avidity and others, that will
define the in vivo effectiveness of a CTL response.
Further complicating our understanding of the relative im-
portances of specific CTL populations and HLA restriction for
HIV control are factors such as epitope competition in indi-
viduals with different HLA backgrounds, variable epitope
dominance patterns, the possible effects of other coinfections,
and often extensive sequence variation in the targeted HIV
epitope itself (19). In the present study, we attempted to elim-
inate some of these potential biases by assessing functional
avidities for CTL responses targeting the same epitopes pre-
sented by several different HLA class I alleles, particularly
those associated with different HIV disease progression rates.
For all tested epitopes with promiscuous HLA restriction, the
alleles associated with superior HIV disease control restricted
responses with higher functional avidities than the less bene-
ficial alleles, even if the responses in the beneficial alleles were
tested in samples from a noncontroller individual. These find-
ings suggest that the restricting allele may be a more potent
determinant of functional avidity within the CTL population
than the bound peptide, which would be in line with recent
data that link specific residues within beneficial HLA allele
sequences with relative viral control (64).
Functional avidity is an indirect measure of the strength of
the interaction between the T cell and its target cell (e.g., an
HIV-infected cell) and depends among other factors on the
monomeric affinity of the clonotypic TCR for cognate pMHC
antigen (72). In paired analyses of epitope-specific CTL re-
sponses, high levels of functional avidity were associated with
narrower TCR repertoires in our study. This observation is
consistent with interclonal competition for antigen, which has
been shown to drive oligoclonal and highly skewed epitope-
specific TCR repertoires in persistent DNA virus infections
(67). Previous work has associated public TCR usage in re-
sponse to the protective Mamu-A*01-restricted Gag CM9
epitope during acute infection with relative control of SIV
replication (65). The observation may be due to an intrinsically
higher level of cross-reactivity among public clonotypes, which
are also present in the naive T-cell pool at greater precursor
frequencies and can therefore be mobilized more readily (68).
It remains to be determined, however, whether the greater
representation of public clonotypes in controllers is associated
with functional avidity per se and how the allele’s intrinsic
ability to restrict cross-reactive responses could impact these
results. In addition, differential TCR
 chain pairing (56) could
potentially complicate the overall interpretation. Indeed, such
pairing promiscuity could explain why the same public TCR	
sequences were subdominant in the three noncontrollers stud-
ied here. Alternatively, these clonotypes may be inefficiently
selected in noncontrollers due to greater immune dysregula-
tion or could perhaps be waning due to higher rates of senes-
cence and clonal turnover under conditions of rampant viral
replication (4). Such ongoing viral replication also increases
viral diversity, and this might lead to the emergence of escape
variants that can induce new T-cell populations at later time
points in infection (3, 37). These variant-specific CTL popula-
tions may possess functional avidity different from that of the
wild-type-specific CTL population and may broaden the TCR
repertoire of the epitope-specific response. This possibility
cannot be ruled out in the present study, where responses were
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not studied longitudinally and under inclusion of all autolo-
gous viral epitope variants. As a consequence, the elevated
functional avidity in HIV controllers may reflect a certain bias
caused by measuring epitope-specific responses in HIV con-
trollers that target nonmutated epitopes and score with a
higher avidity than responses in HIV noncontrollers that may
harbor more-avid responses reactive with autologous epitope
variants but which may not be detected in our assay system
using consensus-based peptides.
Most studies aimed at understanding the characteristics of
protective immune responses to HIV are confronted with
difficulties in disentangling cause versus consequence of the
tested markers. In the SIV model, a progressive decline of
functional avidity has been observed with increasing time of
infection (61), which has been suggested to reflect early
escape of epitopes targeted by high-avidity responses. This
would be in line with recent data on a selected HLA-B*27
epitope showing the gradual escape from high-avidity CTL
responses (39). To indirectly address this point in our anal-
yses and to test whether or not removal of antigen would
result in the (re)emergence of high-avidity responses, chron-
ically HIV infected individuals were studied before and dur-
ing HAART therapy. Somewhat surprisingly, a decline
rather than a recuperation of functional avidity was ob-
served, suggesting that reduction of high antigen doses is
not sufficient to select for high-avidity responses. Obviously,
HAART-induced suppression and spontaneous viral control
are very different situations, and the data may simply be a
reflection of the previously active viral replication and its
effects on the CTL function during the pre-HAART period.
In particular, ongoing viral replication could have led to
immune alterations in chronic progressive infection, which
might no longer be reversible upon HAART initiation, in-
cluding post-TCR signaling pathway dysfunction, increased
cell turnover, and likely other mechanisms (41, 71). Alter-
natively, high-avidity effector CTL may be more affected by
antigen removal than their low-avidity counterparts and/or
the persisting memory pool may be skewed toward certain
clonotypes upon the initiation of HAART. However, the
clonotypic composition of epitope-specific T-cell popula-
tions is thought to remain relatively stable during HAART
(84), which would tend to invoke interclonal qualitative
differences. In this regard, one potential explanation for the
observed reduction could be the preferential activation of
memory T cells that are cross-reactive with other persistent
pathogens and thus might not exhibit the highest functional
avidities for the cognate HIV antigen (19). Clearly, longi-
tudinal studies of untreated individuals starting in acute
infection simultaneously controlling for changes in TCR
repertoire, viral sequence evolution, phenotypic T-cell char-
acteristics, immune dysfunction, and functional avidity will
be required to resolve these questions.
Despite some limitations, the present study provides strong
evidence, on a cross-sectional basis and in the context of a
broad HLA background, for a direct association between the
presence of high-functional-avidity CTL responses and relative
control of HIV replication in vivo. These findings have sub-
stantial implications for HIV vaccine design, which may need
to focus on the induction of CTL responses with high levels of
functional avidity through the mobilization of optimal epitope-
specific TCR repertoires and targeting highly conserved re-
gions to reduce immune escape.
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